Novartis (NVS) discontinued development of VHB937 for amyotrophic lateral sclerosis, the company said in an emailed statement to MT Newswires Wednesday.
The decision was taken after a phase 2 Astrals study did not meet its primary or secondary endpoints.
The company said it remains committed to sharing the study findings and applying the learnings from the research to advance scientific understanding of neurodegenerative diseases.
Price: 139.59, Change: +0.97, Percent Change: +0.70
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.